Cardiol Therapeutics (CRDL) Projected to Post Quarterly Earnings on Monday

Cardiol Therapeutics (NASDAQ:CRDL) is expected to issue its quarterly earnings data before the market opens on Monday, April 21st. Analysts expect Cardiol Therapeutics to post earnings of ($0.09) per share for the quarter.

Cardiol Therapeutics (NASDAQ:CRDL) last released its earnings results on Monday, March 31st. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01. On average, analysts expect Cardiol Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cardiol Therapeutics Stock Performance

Shares of NASDAQ:CRDL opened at $1.01 on Friday. The stock has a market capitalization of $83.44 million, a price-to-earnings ratio of -2.59 and a beta of 1.00. Cardiol Therapeutics has a 1-year low of $0.77 and a 1-year high of $3.12. The company has a 50 day moving average price of $1.07 and a 200 day moving average price of $1.40. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.49 and a current ratio of 2.49.

Wall Street Analyst Weigh In

CRDL has been the topic of a number of recent research reports. Rodman & Renshaw assumed coverage on Cardiol Therapeutics in a report on Tuesday, January 28th. They issued a “buy” rating and a $7.00 target price on the stock. RODMAN&RENSHAW raised shares of Cardiol Therapeutics to a “strong-buy” rating in a research note on Tuesday, January 28th. Finally, HC Wainwright reissued a “buy” rating and issued a $9.00 target price on shares of Cardiol Therapeutics in a research report on Wednesday. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $8.40.

About Cardiol Therapeutics

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.